XOMA XOMA Royalty (XOMA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000791908
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
57
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $20.2M priced
What the filings say about XOMA
Activist stakes (13D), 180 days
1 filing
Largest: 47.0% of the class
XOMA Royalty insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for XOMA Royalty Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 8 earlier Form 4 trades (code P or S) here by this insider (6 buys, 2 sales), the last on May 20, 2025.
- +0.0% median (+0.0% mean) 90-day return after 5 previous buys.
- The trade is 98.0% of the 102,000 shares held after it.
- No other insider bought within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Hughes Owen bought about $2.5M of XOMA on Dec 4, 2025, the largest insider purchase at the company on our record; 57 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on May 20, 2025.
- The trade is 0.0% of the 30,079 shares held after it.
- No other insider sold within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Finance & CFO BURNS THOMAS M. sold about $552 of XOMA on Sep 22, 2025; 57 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on May 20, 2025.
- The trade is 14.3% of the 30,109 shares held after it.
- No other insider sold within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Finance & CFO BURNS THOMAS M. sold about $154.7K of XOMA on Sep 22, 2025; 57 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on May 20, 2025.
- The trade is 0.0% of the 30,094 shares held after it.
- No other insider sold within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Finance & CFO BURNS THOMAS M. sold about $554 of XOMA on Sep 22, 2025; 57 funds added in the latest 13F quarter.Context
- 22 earlier Form 4 trades (code P or S) here by this insider (22 buys), the last on Apr 7, 2025.
- +0.0% median (+0.0% mean) 90-day return after 13 previous buys.
- The trade is 28.4% of the 7,045 shares held after it.
- No other insider bought within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Investment Officer Sitko Bradley bought about $50.8K of XOMA on Jun 30, 2025; 57 funds added in the latest 13F quarter.73 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
57 funds bought in last quarter
more than 50% of Pharma & Biotech
Revenue
+55.6% year over year
more than 78% of Pharma & Biotech
Margin
306.4% net margin
more than 98% of Pharma & Biotech
Buybacks
$264.0K repurchased, FY to 2026-03-31
below 92% of Pharma & Biotech
Short interest
no short interest reported
The situation: each line is one rule over one dataset
Ligand Pharmaceuticals Incorporated disclosed a 5%+ stake (47.0%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch XOMA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns XOMA: institutional holders (13F)
13F holdings, latest reported quarter
7,593,303 sh
$322.7M
1,697,167 sh
$72.1M
1,605,532 sh
$68.2M
1,114,363 sh
$47.4M
709,247 sh
$30.1M
Congress trades in XOMA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Ligand Pharmaceuticals Incorporated
Activist 13D · 2026-05-01
47.0%
XOMA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
XOMA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Inception Portfolio
$7.3M position · as of 2026-06-30
2.6%
EQ/Morgan Stanley Small Cap Growth Portfolio
$4.9M position · as of 2026-06-30
1.0%
Water Island Event-Driven Fund
$508.6K position · as of 2026-05-31
1.0%
AltShares Event-Driven ETF
$123.9K position · as of 2026-05-31
1.0%
THE ARBITRAGE FUND
$8.3M position · as of 2026-05-31
1.0%
Morgan Stanley Insight Fund
$10.7M position · as of 2026-06-30
0.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Hughes
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.1M
$1.3M
$789.2K
+45%
n/a
2024
$5.8M
$6.4M
$731.5K
+43%
n/a
2023
$2.5M
$2.1M
$5.4M
+1%
n/a
2022
$2.3M
$2.3M
$1.0M
-12%
n/a
2021
$3.5M
$3.5M
$1.1M
-53%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 57 funds added last quarter. Each figure is a federal filing, dated the day it went public.
XOMA financials
Revenue growth
+55.6%
XBRL, annual
Net margin
306.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$48.6M
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM XOMA
| FY Dec 2025 | $52.1M |
| FY Dec 2024 | $28.5M |
| FY Dec 2023 | $4.8M |
| FY Dec 2022 | $6.0M |
| FY Dec 2021 | $38.2M |
| Mar 2026 | $12.3M |
| Dec 2025 | $13.8M |
| Sep 2025 | $9.4M |
| Jun 2025 | $13.1M |
| Mar 2025 | $15.9M |
| Dec 2024 | $8.7M |
| Sep 2024 | $7.2M |
| Jun 2024 | $11.1M |
At each fiscal year end
Single quarter
Net margin, TTM
+69.6%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM XOMA
| FY Dec 2025 | +60.8% |
| FY Dec 2024 | -48.5% |
| FY Dec 2023 | -858.2% |
| FY Dec 2022 | -283.8% |
| FY Dec 2021 | +41.4% |
| Mar 2026 | +36.2% |
| Dec 2025 | +44.4% |
| Sep 2025 | +150.3% |
| Jun 2025 | +70.0% |
| Mar 2025 | +14.9% |
| Dec 2024 | -45.5% |
| Sep 2024 | -239.6% |
| Jun 2024 | +144.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$6.8M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM XOMA
| FY Dec 2025 | $2.9M |
| FY Dec 2024 | -$13.8M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$2.9M |
| Sep 2024 | -$8.6M |
| Jun 2024 | $2.7M |
At each fiscal year end
Single quarter
Debt to equity
1.11x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-03-31
Debt to equity XOMA
| FY Dec 2025 | 1.30x |
| FY Dec 2024 | 1.91x |
| FY Dec 2023 | 1.40x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.13x |
| Mar 2026 | 1.11x |
| Dec 2025 | 1.30x |
| Sep 2025 | 1.24x |
| Jun 2025 | 1.57x |
| Mar 2025 | 1.34x |
| Dec 2024 | 1.91x |
| Sep 2024 | 1.39x |
| Jun 2024 | 1.21x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.07x
TTM operating cash flow over long-term 2026-03-31 plus current 2026-03-31
Cash flow to debt XOMA
| FY Dec 2025 | 0.03x |
| FY Dec 2024 | -0.12x |
| FY Dec 2023 | -0.15x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 1.20x |
| Mar 2026 | 0.07x |
| Dec 2025 | 0.03x |
| Sep 2025 | 0.05x |
| Jun 2025 | -0.03x |
| Mar 2025 | -0.06x |
| Dec 2024 | -0.12x |
| Sep 2024 | -0.13x |
| Jun 2024 | -0.07x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+38.1%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity XOMA
| FY Dec 2025 | +43.5% |
| FY Dec 2024 | -18.4% |
| FY Dec 2023 | -38.4% |
| FY Dec 2022 | -12.9% |
| FY Dec 2021 | +13.8% |
| Mar 2026 | +38.1% |
| Dec 2025 | +43.5% |
| Sep 2025 | +25.1% |
| Jun 2025 | -11.2% |
| Mar 2025 | -3.4% |
| Dec 2024 | -18.4% |
| Sep 2024 | -31.4% |
| Jun 2024 | -17.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+14.0%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets XOMA
| FY Dec 2025 | +12.8% |
| FY Dec 2024 | -6.1% |
| FY Dec 2023 | -21.8% |
| FY Dec 2022 | -11.1% |
| FY Dec 2021 | +10.8% |
| Mar 2026 | +14.0% |
| Dec 2025 | +12.8% |
| Sep 2025 | +8.9% |
| Jun 2025 | -4.1% |
| Mar 2025 | -1.3% |
| Dec 2024 | -6.1% |
| Sep 2024 | -17.2% |
| Jun 2024 | -9.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital XOMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -33.3% |
| FY Dec 2022 | -30.2% |
| FY Dec 2021 | +43.9% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+2.3%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed XOMA
| FY Dec 2025 | +5.2% |
| FY Dec 2024 | -19.4% |
| FY Dec 2023 | -24.0% |
| FY Dec 2022 | -12.1% |
| FY Dec 2021 | +13.2% |
| Mar 2026 | +2.3% |
| Dec 2025 | +5.2% |
| Sep 2025 | +0.9% |
| Jun 2025 | -5.8% |
| Mar 2025 | -13.7% |
| Dec 2024 | -19.4% |
| Sep 2024 | -33.3% |
| Jun 2024 | -24.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
25.59x
close 2026-07-21 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing XOMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$521.0M
market value at close 2026-07-21 on 2026-05-07 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
Enterprise value XOMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.3%
TTM free cash flow over market value at close 2026-07-21
FCF yield XOMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing XOMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-07-21. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $52.1M | $28.5M | $4.8M | $6.0M |
| Operating income | $11.4M | -$40.0M | -$41.8M | -$17.4M |
| Net income | $31.7M | -$13.8M | -$40.8M | -$17.1M |
| EPS (diluted) | 1.46 | -1.65 | -4.04 | -1.98 |
| Operating cash flow | $2.9M | -$13.7M | -$18.2M | -$12.9M |
| Cash | $82.9M | $101.7M | $153.3M | $57.8M |
| Long-term debt | $96.5M | $106.9M | $118.5M | $0 |
| Buybacks | $16.0M | $13.0K | n/a | n/a |
| Dividends paid | $5.5M | $5.5M | $5.5M | $5.5M |
SEC XBRL, fiscal years, as known on 2026-10-27
XOMA Stock Sonar score 5/7 axes
Find similar shapesCompareXOMA ranks highest on profitability (90th percentile) and growth (78th), and lowest on risk and compliance (45th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
XOMA filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 47.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
